The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy
- 1 July 1999
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (7) , 921-926
- https://doi.org/10.1046/j.1365-2036.1999.00556.x
Abstract
Helicobacter pylori exaggerates the effect of acid suppressive drugs on intragastric pH. It is unknown whether this is relevant for the treatment of GERD. To compare oesophageal acid exposure and symptoms in H. pylori-negative and H. pylori-positive GERD patients during low and profound acid suppression. Barrett's oesophagus patients with gastro- oesophageal acid reflux were studied by 24-h oesophageal pH-metry at baseline and during randomized treatment with omeprazole 40 mg b.d. or ranitidine 150 mg b.d. H. pylori status was determined by a serum IgG ELISA. Symptoms were scored on a four-graded scale. Of 58 patients, 26 (14 H. pylori-negative, 12 H. pylori-positive) were randomized to omeprazole, 32 (16 H. pylori-negative, 16 H. pylori-positive) to ranitidine. At baseline, oesophageal acid exposure and symptoms did not differ between H. pylori-negative and H. pylori-positive: mean time proportion pH < 4 per 24 h was 16.1% (95% CI 11.5-23.2) in H. pylori-negative, and 15.8% (11.3-21.4) in H. pylori-positive patients. Omeprazole treatment resulted in a decrease of acid reflux per 24 h from 23.4% (7.9-39.3) to 0.0% (0.0-2.9) in H. pylori-negative, and from 17.3% (8.9-38.8) to 0.1% (0.0-1.7) in H. pylori-positive patients; ranitidine resulted in a decrease from 14.4% (10.5-18.5) to 9.3% (5.6-12.8) in H. pylori-negative, and from 15.1% (9.8-21.0) to 9.0% (3.1-20.1) in H. pylori-positive patients, the difference between H. pylori-negative and H. pylori-positive patients being N.S. There was no significant difference between H. pylori-negative and H. pylori-positive patients with respect to erect and supine acid reflux, or symptom scores in both treatment groups. H. pylori infection does not influence oesophageal acid reflux and symptoms in patients with Barrett's oesophagus, either at baseline or during low as well as profound acid suppressive therapy. We conclude that the dose of acid suppression does not have to be titrated upon H. pylori status in GERD.Keywords
This publication has 15 references indexed in Scilit:
- The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitisEuropean Journal of Gastroenterology & Hepatology, 1998
- Does cure of Helicobacter pylori infection induce heartburn?Gastroenterology, 1998
- No increase of reflux symptoms or esophagitis in patients with non-ulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomized double-blind placebo-controled trialGastroenterology, 1998
- Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.Gut, 1997
- Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus.Gut, 1997
- Helicobacter pylori Infection Has No Role in the Pathogenesis of Reflux EsophagitisDigestive Diseases and Sciences, 1997
- Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett’s esophagusDiseases of the Esophagus, 1997
- Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcerGastroenterology, 1996
- Value of Serology (ELISA and Immunoblotting) for the Diagnosis of Campylobacter pylori InfectionDigestion, 1989
- The Histologic Spectrum of Barrett's EsophagusNew England Journal of Medicine, 1976